Creatine on GLP-1: Lean Mass Preservation, Hydration, and Combined Use Evidence

TL;DR — what creatine actually does on a GLP-1

GLP-1 receptor agonists (semaglutide in Wegovy, tirzepatide in Zepbound) produce real, sustained fat-mass loss — but roughly 25% of the weight lost is lean mass, not fat, per the SURMOUNT-1 DXA body-composition substudy.^[3] That lean-mass loss is not unique to GLP-1s — the same proportional split is seen with caloric restriction alone — but because GLP-1s produce larger absolute weight loss, the absolute amount of lean mass lost is also larger.

Creatine monohydrate, when combined with resistance training, is the most well-evidenced dietary supplement for amplifying lean mass retention during a caloric deficit. The International Society of Sports Nutrition (ISSN) position stand classifies it as the most-effective ergogenic nutritional supplement for increasing high-intensity exercise capacity and lean body mass.^[4]

The key clinical points for GLP-1 users in 2026:

• No pharmacokinetic interaction between creatine and any FDA-approved GLP-1 exists or is listed in any GLP-1 prescribing information.
• The hydration interplay matters: creatine increases intracellular water by roughly 0.5–1.5 kg, and GLP-1 GI side effects can cause dehydration — adequate fluid intake bridges both concerns.
• Resistance training is the load-bearing intervention; creatine amplifies it. No supplement replaces lifting.
• In people with normal kidney function, creatine at 3–5 g/day is well-tolerated long-term; patients with reduced GFR or chronic kidney disease should consult their prescriber before use.

The lean mass loss problem on GLP-1s

SURMOUNT-1 DXA substudy: the 75 / 25 finding

The most rigorous body-composition data for the GLP-1 class comes from the SURMOUNT-1 DXA substudy published in Diabetes, Obesity and Metabolism in 2025 (Look et al., PMID 39996356). A subset of 160 participants from the 2,539-person SURMOUNT-1 trial underwent dual-energy X-ray absorptiometry (DXA) at baseline and at Week 72. This is radiology-grade measurement of body composition — not scale weight, not bioimpedance — and it produced the most precise picture of what tirzepatide does to body composition.

“The change in body weight, fat mass and lean mass from baseline to Week 72 was −21.3%, −33.9% and −10.9% with tirzepatide and −5.3%, −8.2% and −2.6% with placebo, respectively (p < 0.001 for all comparisons). Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.”

Source: Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2720–2729. PMID 39996356. DailyMed SetID for Zepbound: 487cd7e7-434c-4925-99fa-aa80b1cc776b. Verified 2026-05-10.

Three things about this finding are worth parsing carefully:

1. The 25% lean-mass proportion is consistent across doses and is not unique to tirzepatide. The placebo arm had the same ~75/25 split, which means this is not a drug-specific effect — it is the physiology of rapid caloric restriction. GLP-1s make fast, large weight loss accessible to millions of people who previously could not achieve it; the lean-mass trade-off is the same as with any other rapid-restriction strategy.
2. The absolute lean mass lost is larger because the absolute weight loss is larger. A participant losing 21 kg loses roughly 5.25 kg of lean mass (25%). That is clinically meaningful, particularly in older adults, post-menopausal women, and people with pre-existing sarcopenic obesity.
3. The tirzepatide arm lost 10.9% of lean mass at Week 72. This is a real reduction — not trivial — but it occurred alongside a 33.9% reduction in fat mass. From a metabolic-health standpoint, the trade is heavily favorable, but the lean-mass loss is a modifiable risk factor with an established intervention: resistance training plus adequate protein, with creatine as an adjunct.

Wegovy Section 14.2: the STEP-1 efficacy context

The Wegovy (semaglutide) prescribing information Section 14.2 (Weight Reduction and Long-term Maintenance Studies in Adults) documents the primary efficacy results for Study 2 (NCT03548935), corresponding to the published STEP-1 trial (PMID 33567185):

Least-squares mean percent change in body weight from baseline at Week 68: placebo −2.4%, semaglutide 2.4 mg −14.9%. Percent difference from placebo (LSMean): −12.4 (95% CI −13.3 to −11.6).

Source: Wegovy (semaglutide) prescribing information, Section 14.2. DailyMed SetID: ee06186f-2aa3-4990-a760-757579d8f77b (Novo Nordisk). Verified 2026-05-10.

The Wegovy Section 12.1 Mechanism of Action notes that semaglutide “acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.” This appetite-suppression mechanism drives the caloric deficit that produces weight loss — and by extension, the lean-mass loss that follows any large caloric deficit.

Who is at highest risk of clinically meaningful lean-mass loss

The 25% lean-mass proportion matters more in some patients than others. The groups most at risk of functional impairment from lean-mass loss during GLP-1 therapy are:

• Adults over 60. Sarcopenia (age-related muscle loss) is already progressing at baseline; a 5-kg additional lean-mass reduction can shift a borderline patient into clinical sarcopenia with its associated fall risk and functional decline.
• Post-menopausal women. Estrogen decline reduces anabolic signaling in muscle; the same caloric deficit produces more lean-mass loss in post-menopausal women than in pre-menopausal women at comparable body weight.
• Patients with sarcopenic obesity at baseline. Carrying excess fat while already being low in lean mass — increasingly common in metabolic syndrome — means the absolute lean-mass reserve is smaller, and the 25% proportion removes a larger share of an already reduced buffer.
• Patients losing weight rapidly without resistance training. The faster the weight loss, the higher the proportion from lean mass. Patients who rely on GLP-1 appetite suppression alone, without structured resistance training, will trend toward the worse end of the lean-mass loss distribution.

Why creatine + resistance training preserves lean mass

ISSN position stand: what the evidence says

The International Society of Sports Nutrition (ISSN) published its comprehensive position stand on creatine supplementation in 2017 in the Journal of the International Society of Sports Nutrition (Kreider et al., PMID 28615996). This is the field's primary regulatory-grade synthesis of creatine evidence — more than 500 studies reviewed across safety, efficacy, and mechanisms.

The ISSN position stand makes several findings directly relevant to GLP-1 users concerned about lean-mass loss:

• Creatine is “the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass during training.”^[4]
• Short-term creatine supplementation (5–7 day loading at 20 g/day) produces a mean lean body mass gain of approximately 1–2 kg, largely from intracellular water retention in the first week. Long-term supplementation combined with resistance training produces additional lean mass gains beyond water, reflecting genuine muscle hypertrophy.
• The evidence for creatine in older adults is particularly relevant: the position stand notes that creatine combined with resistance training “has been found to be safe and to generally produce increases in strength, power, and lean body mass in older adults” — exactly the population at highest risk of GLP-1-related lean-mass loss.^[4]
• Creatine does not appear to work meaningfully without the resistance training stimulus. The ISSN position stand is explicit: creatine supplementation amplifies the adaptive response to mechanical loading. Without that loading signal, the effect on lean mass is modest.

The mechanism: why creatine amplifies the training response

Creatine (as creatine phosphate in muscle) is the primary substrate for rapid ATP resynthesis during high-intensity muscular contractions lasting fewer than about 10 seconds. By increasing the intramuscular creatine phosphate pool (standard supplementation increases muscle creatine content by approximately 20–40% above baseline), creatine supplementation allows:

1. More reps at a given load — patients can complete one to two additional repetitions in the 3–8 rep range before fatigue, incrementally increasing the mechanical stimulus to the muscle.
2. More total training volume — across a resistance training session, the additional reps add up to meaningfully more total work done, which is the primary driver of hypertrophic adaptation.
3. Faster between-set recovery — creatine phosphate resynthesis between sets is faster when the pool is fully saturated, allowing more complete recovery and higher quality subsequent sets.

In a GLP-1 context, patients are in a caloric deficit of several hundred calories per day. This deficit impairs muscle protein synthesis and increases protein catabolism. Resistance training is the anabolic signal that partially counteracts catabolism. Creatine amplifies the quality and volume of that training signal — which is why the combination (creatine + resistance training) outperforms either intervention alone for lean mass retention.

Creatine and lower-limb strength: meta-analytic evidence

Lanhers et al. (2015, PMID 25946994) conducted a systematic review and meta-analysis of creatine supplementation and lower-limb strength performance in Sports Medicine. Lower-limb strength — particularly knee extension and leg press performance — is the functional muscle most relevant to fall risk and functional independence in older adults on GLP-1 therapy. The review found that creatine supplementation produced significant improvements in lower-limb strength, consistent with the ISSN position stand's broader lean mass findings.^[7]

Drug interactions between creatine and GLP-1s: what the FDA labels say

Creatine is a dietary supplement, not a prescription drug — but it is worth being precise about what the FDA prescribing information says about interactions. The answer, directly from each label, is that creatine is not mentioned.

Wegovy (semaglutide) Section 7: verbatim

“7.1 Concomitant Use with Insulin or an Insulin Secretagogue (e.g., Sulfonylurea): WEGOVY lowers blood glucose and can cause hypoglycemia. The risk of hypoglycemia is increased when WEGOVY is used concomitantly with insulin or insulin secretagogues (e.g., sulfonylureas). [...] 7.2 Oral Medications: WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials with semaglutide 1 mg once weekly injection, semaglutide did not affect the absorption of orally administered medications [see Clinical Pharmacology (12.3)].”

Source: Wegovy (semaglutide) prescribing information, Section 7. DailyMed SetID: ee06186f-2aa3-4990-a760-757579d8f77b (Novo Nordisk). Verified 2026-05-10.

Creatine monohydrate powder is not an oral drug with a narrow therapeutic index, not an insulin secretagogue, and not a drug requiring clinical monitoring. It is not addressed anywhere in the Wegovy prescribing information.

Zepbound (tirzepatide) Section 7: verbatim

“7.2 Oral Medications: ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND.”

Source: Zepbound (tirzepatide) prescribing information, Section 7. DailyMed SetID: 487cd7e7-434c-4925-99fa-aa80b1cc776b (Eli Lilly and Company). Verified 2026-05-10.

Creatine monohydrate, like most dietary supplement powders, is not an oral medication with threshold-concentration pharmacodynamics. It does not require clinical monitoring and does not have a narrow therapeutic index. The Zepbound Section 7 warning targets drugs where small changes in plasma concentration have clinical consequences — examples given in the label include warfarin.

Interaction bottom line: no pharmacokinetic concern; clinical considerations exist

To be precise about the distinction:

• Pharmacokinetic interaction (formal drug-drug interaction): None. Neither GLP-1 label lists creatine, nor is there any published pharmacokinetic study showing that creatine alters semaglutide or tirzepatide plasma concentrations, half-life, or receptor binding.
• Clinical considerations that do apply: (1) Hydration — addressed in detail in the section below. (2) Kidney function monitoring — creatine elevates serum creatinine modestly, which can confound eGFR calculations. If your prescriber monitors kidney function regularly, let them know you are using creatine so they can interpret your creatinine lab correctly. (3) GI tolerance — creatine in 5 g increments is generally well-tolerated, but during GLP-1 titration when GI symptoms are most prevalent, adding another GI supplement may compound nausea in some patients.

The standard recommendation: inform your prescriber that you are using creatine — not because of a known interaction, but because it alters a standard lab value (serum creatinine) and because clinical context matters.

The hydration question

Creatine's effect on intracellular water

Creatine supplementation increases water uptake into muscle cells. The mechanism is osmotic: creatine is accumulated intracellularly via a sodium-dependent transporter, and water follows the osmotic gradient. During loading (20 g/day for 5–7 days), the scale commonly increases by 0.5–1.5 kg within the first week. On a maintenance-only protocol (3–5 g/day without loading), the water increase occurs more gradually over 3–4 weeks and often amounts to 0.5–1.0 kg.

This is intracellular water — not edema, not interstitial fluid, not subcutaneous water retention from excess sodium. It represents water stored inside muscle cells alongside the creatine molecule. It is metabolically inert and reverses within 2–4 weeks of stopping creatine. On the scale, it looks like a plateau or modest gain; on DEXA, it appears as a small increase in lean mass (because DEXA cannot distinguish intracellular water from protein). On a practical body-composition basis, this water retention is neither harmful nor beneficial — it is simply a pharmacologic effect of creatine saturation.

For GLP-1 users, this means: if you start creatine during a Wegovy or Zepbound plateau, the scale may not budge or may increase slightly for 1–2 weeks. Do not interpret this as a loss of medication efficacy. Fat loss continues even while creatine water is accumulating. Waist circumference measurement or DEXA confirms continued fat-loss progress when the scale is ambiguous.

GLP-1 GI side effects and dehydration risk

While creatine increases intracellular water, GLP-1 GI adverse effects can cause the opposite problem systemically. Both the Wegovy and Zepbound prescribing information carry explicit kidney injury warnings tied specifically to GI-driven dehydration.

Wegovy Section 5.5 — Acute Kidney Injury Due to Volume Depletion: “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation of WEGOVY.”

Source: Wegovy (semaglutide) prescribing information, Section 5.5. DailyMed SetID: ee06186f-2aa3-4990-a760-757579d8f77b. Verified 2026-05-10.

Zepbound Section 5.3 — Acute Kidney Injury Due to Volume Depletion: “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or ZEPBOUND. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea. Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion, especially during dosage initiation and escalation.”

Source: Zepbound (tirzepatide) prescribing information, Section 5.3. DailyMed SetID: 487cd7e7-434c-4925-99fa-aa80b1cc776b. Verified 2026-05-10.

The combined picture: creatine makes the body need more water (to maintain intracellular creatine stores and support the osmotic load), while GLP-1 side effects can reduce the body's fluid balance through nausea-driven reduced intake, vomiting, and diarrhea. These are not additive toward acute kidney injury — creatine does not cause extracellular dehydration — but the practical guidance is straightforward:

• Drink at least 2.5–3 liters of water per day when combining creatine with a GLP-1, more on resistance training days.
• During any GI flare (nausea, vomiting, diarrhea), prioritize rehydration with an electrolyte-containing fluid rather than plain water, and consider temporarily suspending the creatine dose until GI symptoms resolve.
• Severe GI symptoms causing volume depletion warrant contacting your prescriber — this is the clinical scenario the FDA label warnings are specifically addressing.

Loading vs maintenance dosing on a GLP-1

The ISSN position stand (PMID 28615996) documents the two standard creatine supplementation strategies:^[4]

GI tolerance during GLP-1 titration: practical guidance

The decision between loading and maintenance on a GLP-1 hinges on where you are in the titration schedule. GLP-1 GI side effects are most common during dose escalation — the first 4–16 weeks of treatment. During this window, adding four 5 g creatine doses per day on top of an already GI-active medication can amplify nausea in some patients, particularly when creatine is taken without food.

Practical guidance for GLP-1 users starting creatine:

• If you are past the initial titration phase and tolerating your current dose well: Loading is an option if faster muscle creatine saturation is a priority. Divide the 20 g into four 5 g doses, take each with food, and maintain high fluid intake.
• If you are still in the titration window (first 3–4 months) or experiencing active GI symptoms: Skip loading. Start at 3–5 g/day with a full meal. You will reach the same steady-state creatine levels as a loading protocol — just 3 weeks later.
• Timing relative to the GLP-1 injection: Creatine is not absorbed through a mechanism affected by gastric emptying delay. It is taken as a powder dissolved in water or juice and absorbed via sodium-dependent transporters in the small intestine. Gastric emptying delay from the GLP-1 may slightly slow creatine absorption, but this has no meaningful clinical effect on steady-state muscle creatine levels.
• Form of creatine: Creatine monohydrate remains the best-evidenced form per the ISSN position stand.^[4] Creatine HCl, buffered creatine, and other marketed variants have not demonstrated superiority over monohydrate for lean mass outcomes and are generally more expensive.

As always — discuss supplement use with your GLP-1 prescriber, both to ensure they are aware and to receive guidance tailored to your specific clinical situation.

Resistance training is the load-bearing intervention; creatine is adjunct

This distinction is worth being direct about, because supplement marketing around GLP-1 weight loss has a financial incentive to overstate what any single supplement can do. The evidence is unambiguous on the hierarchy:

1. Adequate protein intake (1.6–2.2 g/kg/day) is the single most important nutritional variable for lean mass preservation during a caloric deficit. Morton et al. (2018, PMID 28698222) published the definitive meta-analysis: across 49 studies and 1,863 participants, protein supplementation had a robust, dose-dependent effect on resistance-training-driven lean mass gains.^[5] The effect was strongest when habitual protein intake was below 1.6 g/kg/day — which describes many GLP-1 patients whose appetite suppression has sharply reduced caloric and protein intake.
2. Resistance training 2–3 times per week targeting compound movements (squat pattern, hip hinge, horizontal push, horizontal pull) is the anabolic stimulus that signals muscle tissue to be preserved rather than catabolized. Without this mechanical loading signal, no supplement provides more than modest lean-mass benefit.
3. Creatine monohydrate 3–5 g/day amplifies the training response when both of the above are already in place. The ISSN position stand is explicit: creatine's lean-mass effect depends on a concurrent resistance training program.^[4]

The clinical reasoning: GLP-1 appetite suppression reduces total caloric intake dramatically — in STEP-1, the drug produced a -14.9% reduction in body weight across 68 weeks.^[1] This caloric deficit is the engine of fat loss. The same deficit, however, is catabolic to muscle unless countered by a training-and-protein signal that tells the body to preferentially oxidize fat rather than break down muscle protein for energy.

Creatine has no meaningful ability to signal muscle preservation on its own. What it does is allow you to do more total training volume per session — more reps, heavier loads, shorter rest periods before performance degrades — which amplifies the anabolic signal. In the context of GLP-1 use, where appetite suppression and caloric deficit are already imposing a catabolic pressure on muscle, a stronger training stimulus matters more, not less. That is where creatine earns its role.

The practical implication: patients who are doing resistance training twice a week and eating 1.6+ g/kg of protein per day will likely benefit from adding creatine. Patients who are doing no resistance training and expecting creatine to prevent lean-mass loss will be disappointed. Prioritize in that order.

Body composition tracking: DEXA, bioimpedance, and waist measurement

A central challenge in managing lean mass on GLP-1 therapy is that the scale is an unreliable indicator of body composition progress. Creatine adds intracellular water (which increases scale weight), GLP-1 therapy burns fat (which decreases scale weight), and the two can partially cancel each other out on the scale, creating misleading readings during the first weeks of combined use.

DEXA (dual-energy X-ray absorptiometry)

DEXA is the reference standard for body composition measurement in clinical trials, including the SURMOUNT-1 body-composition substudy.^[3] It measures fat mass, lean mass, and bone mineral content as distinct compartments with high precision. Cost is typically $50–$150 out of pocket at sports medicine clinics, university sports science labs, or medical weight-loss practices. A baseline DEXA before starting a GLP-1, and a follow-up at 6 months, provides the most actionable picture of whether lean mass is being preserved. Key limitation: creatine increases intracellular water, which DEXA classifies as lean mass — so a small apparent lean mass gain in the first month of creatine use may partly reflect water, not actual muscle protein accretion.

Bioimpedance analysis (BIA)

Consumer bioimpedance scales and professional InBody-style BIA devices estimate body composition by passing a low-level electrical current through the body. The current travels faster through water and muscle than through fat. The accuracy limitation: BIA is sensitive to hydration state. Because creatine increases intracellular water, BIA will systematically overestimate lean mass gains during creatine loading. BIA measurements are more reliable when taken under consistent conditions — same time of day, same hydration state, same point in the creatine supplementation protocol (after saturation is established, not during loading). For directional tracking over months, BIA is reasonably useful. For precise week-to-week body composition readings, it is not reliable enough on creatine.

Waist circumference

Waist circumference is underused in clinical practice but is a robust proxy for visceral fat reduction — the metabolically significant fat that drives cardiometabolic risk. In the SURMOUNT-1 body-composition substudy, waist circumference reduction was among the documented outcomes of tirzepatide treatment.^[3] For patients who want a practical, no-cost method for confirming that fat loss is progressing while creatine water weight obscures the scale: measure waist circumference at the navel weekly, under consistent conditions (morning, post-void, before eating). A downward trend in waist circumference alongside a flat or rising scale is strong evidence that creatine water retention and fat loss are occurring simultaneously.

What about other supplements: protein powder, BCAAs, HMB?

Protein adequacy: the first priority

The Morton et al. 2018 meta-analysis (PMID 28698222) across 49 studies found that protein supplementation significantly increased lean mass gains from resistance training. The effect was consistent across age groups and training statuses, with the largest gains when total protein intake was below 1.6 g/kg/day.^[5] For GLP-1 users whose appetite suppression has sharply reduced food intake, reaching 1.6–2.2 g/kg/day of protein through whole foods alone can be difficult. Protein powder — whey, casein, or a plant-based blend with leucine — is a practical way to close the protein gap without adding excessive calories. A 30 g scoop of whey protein delivers approximately 25 g of protein with 120–130 kcal and does not significantly affect GLP-1 pharmacology. Protein adequacy is more important than any single supplement.

BCAAs (branched-chain amino acids)

BCAAs (leucine, isoleucine, valine) are sometimes marketed as anti-catabolic supplements for weight loss. When total protein intake is already adequate (1.6+ g/kg/day), BCAA supplementation adds no additional lean-mass benefit. BCAAs are a subset of the amino acids already present in complete protein; supplementing isolated BCAAs while eating adequate complete protein is not supported by trial evidence as an additional lean-mass intervention. If protein intake is below target, completing it with a whole-protein source is more effective and more cost-efficient than adding isolated BCAAs.

HMB (beta-hydroxy beta-methylbutyrate)

HMB is a metabolite of leucine with anti-catabolic properties studied primarily in sarcopenic and bedridden populations. The evidence in healthy, exercising individuals is substantially weaker than for creatine. The ISSN position stand notes that HMB effects are most pronounced in untrained individuals or those experiencing severe catabolism (illness, immobilization). For most GLP-1 users who are ambulatory and doing resistance training, creatine is better supported by the evidence base than HMB. HMB may be worth considering in the context of GLP-1 use in older adults with significant frailty or reduced exercise capacity where resistance training intensity is genuinely limited.

The practical hierarchy

For GLP-1 users concerned about lean mass, the supplement hierarchy by evidence quality is:

1. Protein adequacy (1.6–2.2 g/kg/day). Not optional. Supplement with protein powder if whole-food intake falls short.
2. Creatine monohydrate (3–5 g/day). Well-evidenced, inexpensive, safe in normal kidney function. The strongest lean-mass amplifier for patients doing resistance training.^[4]
3. Vitamin D (if deficient). Vitamin D deficiency impairs muscle protein synthesis; repletion in deficient patients supports muscle function.
4. BCAAs, HMB, other amino acid blends: Not necessary with adequate protein intake. May have marginal benefit in specific clinical contexts (severe sarcopenia, HMB in immobilized patients).

Is creatine safe long-term on a GLP-1?

The Butts, Jacobs, and Silvis (2018) clinical review in Sports Health (PMID 29059531) summarizes the safety profile of creatine from the current literature: “Short-term use of creatine is considered safe and without significant adverse effects in healthy individuals.”^[6] The review also notes that long-term use (years) in healthy populations has not been shown to impair kidney function.

The ISSN position stand (PMID 28615996) is more detailed: creatine supplementation does not adversely affect kidney function in healthy individuals without pre-existing kidney disease, citing multiple controlled trials including trials of up to 5 years of continuous use.^[4]

Kidney function caveats

Two specific caveats apply to GLP-1 users:

1. Serum creatinine interpretation. Creatine supplementation increases serum creatinine — a standard kidney function marker used to calculate eGFR — by a small but measurable amount. This does not reflect actual kidney injury; it reflects increased creatinine turnover from the supplemented creatine load. Clinically, this means that an eGFR calculated using a serum creatinine drawn while you are on creatine supplementation will slightly underestimate true GFR. Tell your prescriber you are taking creatine so that any eGFR change can be interpreted in context. Both the Wegovy and Zepbound labels instruct prescribers to monitor renal function during GI side effects. If your prescriber orders a kidney panel, the creatine context matters for interpretation.
2. Pre-existing kidney disease. Patients with chronic kidney disease (CKD stage 3+, eGFR below 60), proteinuria, or a history of kidney disease should consult their nephrologist or prescriber before starting creatine. There is no definitive trial evidence that creatine is unsafe in mild-moderate CKD, but neither is there robust evidence that it is safe — the evidence base simply excludes patients with significant kidney disease. Given that both Wegovy and Zepbound carry explicit kidney injury warnings for volume depletion, and given that any confounding of kidney function labs matters more in a patient with reduced baseline GFR, the conservative approach is individualized prescriber guidance.

In patients without kidney disease, using creatine at standard doses (3–5 g/day) during GLP-1 therapy does not impose a kidney safety concern beyond the routine requirement to maintain adequate hydration — a requirement that applies independently of creatine use.

What to tell your prescriber

GLP-1 prescribers are increasingly familiar with patients who ask about creatine, protein powder, and resistance training for lean mass preservation. Here is a concise way to frame the conversation:

• “I'm planning to start creatine monohydrate at 3–5 g/day. I know it raises serum creatinine slightly — I wanted you to be aware so that any kidney function labs are interpreted correctly.”
• “I have a resistance training program twice a week and I'm tracking protein intake. My goal is to preserve lean mass while losing fat on [Wegovy / Zepbound / Ozempic / Mounjaro].”
• If you have a history of kidney disease, or if your most recent eGFR was below 60: “Can you advise whether creatine is appropriate given my kidney history, and what level of monitoring you'd recommend?”

There is no FDA-labeled contraindication to creatine on any GLP-1. Your prescriber's role here is clinical context: your baseline kidney function, your current dose titration schedule, your GI symptom profile, and your overall supplement and medication list. That context cannot be replaced by a research article, however detailed. This article is educational; your prescriber has the clinical picture.

Related research

• Does diarrhea cause weight loss on GLP-1s? Real fat loss vs fluid — companion article covering the fat-vs-lean-mass body composition data from STEP-1 and SURMOUNT-1 DXA, and the FDA-label dehydration and kidney injury warnings in detail. The 75/25 fat-vs-lean split documented here originates from the same SURMOUNT-1 DXA substudy.
• GLP-1 fatigue: mechanisms and management — covers how caloric restriction energy gaps, lean mass loss, and GI dehydration all contribute to fatigue on a GLP-1 — the same mechanistic trio addressed by protein adequacy, resistance training, and creatine.
• Exercise on a GLP-1: the lean mass preservation protocol — the full exercise evidence base for GLP-1 users, including program structure, compound movement selection, and protein targets. Creatine is the adjunct; this article is the primary training framework.
• Ashwagandha and GLP-1: cortisol, stress eating, and combined use evidence — companion article in the supplement-on-GLP-1 vertical. Covers the cortisol/stress-eating mechanism that GLP-1s don't directly address, three verified cortisol RCTs, NIH LiverTox hepatotoxicity classification (Likelihood Score B), thyroid effects, and FDA GLP-1 Section 7 label analysis.
• Semaglutide and muscle mass loss: what the trials show — detailed body composition data across the semaglutide trial program, including how the ~25% lean-mass proportion compares to bariatric surgery and unassisted caloric restriction.
• GLP-1 side effect questions answered — Q&A hub covering 30+ side effect topics including GI symptoms, hydration management, supplement interactions, and when to contact your prescriber.
• Complete GLP-1 medication reference — prescribing information, DailyMed SetIDs, approved indications, and drug interaction summaries for all FDA-approved GLP-1 receptor agonists.